1. Home
  2. PNR vs NTRA Comparison

PNR vs NTRA Comparison

Compare PNR & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pentair plc.

PNR

Pentair plc.

HOLD

Current Price

$104.44

Market Cap

17.1B

Sector

Industrials

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$229.53

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNR
NTRA
Founded
1966
2003
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.1B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
PNR
NTRA
Price
$104.44
$229.53
Analyst Decision
Buy
Strong Buy
Analyst Count
14
15
Target Price
$119.43
$238.20
AVG Volume (30 Days)
1.0M
1.2M
Earning Date
02-03-2026
11-06-2025
Dividend Yield
1.02%
N/A
EPS Growth
N/A
N/A
EPS
3.93
N/A
Revenue
$4,128,399,999.00
$2,116,676,000.00
Revenue This Year
$2.97
$33.18
Revenue Next Year
$4.61
$16.81
P/E Ratio
$26.91
N/A
Revenue Growth
0.83
38.17
52 Week Low
$74.25
$125.38
52 Week High
$113.95
$246.90

Technical Indicators

Market Signals
Indicator
PNR
NTRA
Relative Strength Index (RSI) 45.37 52.01
Support Level $105.18 $227.89
Resistance Level $106.11 $237.04
Average True Range (ATR) 1.67 5.07
MACD 0.15 -1.57
Stochastic Oscillator 29.51 49.47

Price Performance

Historical Comparison
PNR
NTRA

About PNR Pentair plc.

Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: